Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: A large-scale multicenter study of 222 patients

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1786-1792

  Zhao, Y ^a   Wang, W J ^a   Guan, S ^b   Li, H L ^c   Xu, R C ^d   Wu, J B ^e   Liu, J S ^f   Li, H P ^g   Bai, W ^a   Yin, Z X ^a   Fan, D M ^a   Zhang, Z L ^a,h   Han, G H ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c Henan Tumor Hospital   (China)

^d HUNAN CANCER HOSPITAL   (China)

^e NANCHANG UNIVERSITY   (China)

^f Department of Radiology   (China)

^g CENTRAL SOUTH UNIVERSITY   (China)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Sorafenib; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LUNG METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME;

EID: 84880732021     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt072     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. EASL-EORTC clinical practice guidelines:. management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
3. Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-3967.
4. Cabrera R, Pannu DS, Caridi J et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 34: 205-213.
5. Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-2127.
6. Abou-Alfa GK. TACE and sorafenib: a good marriage?. J Clin Oncol 2011; 29: 3949-3952.
7. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
8. Omata M, Lesmana LA, Tateishi R et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
9. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
10. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research andTreatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
12. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
13. Lindor RA, Lindor KD. The value of observational research in liver diseases. Hepatology 2011; 53: 1-3.
14. Hsu CY, Lee YH, Hsia CY et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology 2013; 57: 112-119.
15. Luo J, Guo RP, Lai EC et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-420.
16. Chung GE, Lee JH, Kim HY et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634.
17. Kim KM, Kim JH, Park IS et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009; 24: 806-814.
18. Kudo M, Izumi N, Kokudo N et al. Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
19. Yoo DJ, Kim KM, Jin YJ et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?. J Gastroenterol Hepatol 2011; 26: 145-154.
20. Senthilnathan S, Memon K, Lewandowski RJ et al. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology 2012; 55: 1432-1442.
21. Pinter M, Hucke F, Graziadei I et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263: 590-599.
22. Huitzil-Melendez FD, Capanu M, O'Reilly EM et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. J Clin Oncol 2010; 28: 2889-2895.
23. Dufour JF. TACE with or without systemic therapy?. J Hepatol 2012; 56: 1224-1225.